Vaccination of cancer patients for preventing cancer development

INTERVENTION: After antigen priming, subcutaneous injection of median of 6.5 × 1000000 (0.5 ml) dendritic cells, close to inguinal lymph nodes, twice a day After antigen priming, subcutaneous injection of median of 6.5 × 1000000 (0.5 ml) dendritic cells, close to inguinal lymph nodes, twice a day. CONDITION: B‐cell lymphoma, unspecified Lymphoma. ; B‐cell lymphoma, unspecified PRIMARY OUTCOME: The number of TCD4. Timepoint: one week after injection. Method of measurement: Flocytometry. The number of TCD8. Timepoint: one week after injection. Method of measurement: Flocytometry. SECONDARY OUTCOME: Interleukin 2. Timepoint: 7 to 14 days after injection. Method of measurement: eliza. Interleukin 10. Timepoint: 7 to 14 days after injection. Method of measurement: ELIZA method. Interleukin 17. Timepoint: 7 to 14 days after injection. Method of measurement: ELIZA method. Interleukin 4. Timepoint: 7 to 14 days after injection. Method of measurement: ELIZA method. INCLUSION CRITERIA: INCLUSION CRITERIA: Presence of diffuse b cell lymphoma Exclusion criteria: Presence o any other kind of cancer except for lymphoma